The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
N-Terminal Pro–B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation
Open accessAbstract
Objectives This study sought to assess the prognostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with atrial fibrillation (AF) enrolled in the ARISTOTLE (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation) trial, and the treatment effect of apixaban according to NT-proBNP levels.Background Natriuretic peptides are associated with mortality and cardiovascular events in several cardiac diseases.Methods In the ARISTOTLE trial, 18,201 patients with AF were randomized to apixaban or warfarin. Plasma samples at randomization were available from 14,892 patients. The association between NT-proBNP concentrations and clinical outcomes was evaluated using Cox proportional hazard models, after adjusting for established cardiovascular risk factors.Results Quartiles of NT-proBNP were: Q1, ≤363 ng/l; Q2, 364 to 713 ng/l; Q3, 714 to 1,250 ng/l; and Q4, >1,250 ng/l. During 1.9 years, the annual rates of stroke or systemic embolism ranged from 0.74% in the bottom NT-proBNP quartile to 2.21% in the top quartile, an adjusted hazard ratio of 2.35 (95% confidence interval [CI]: 1.62 to 3.40; p < 0.0001). Annual rates of cardiac death ranged from 0.86% in Q1 to 4.14% in Q4, with an adjusted hazard ratio of 2.50 (95% CI: 1.81 to 3.45; p < 0.0001). Adding NT-proBNP levels to the CHA2DS2VASc score improved C-statistics from 0.62 to 0.65 (p = 0.0009) for stroke or systemic embolism and from 0.59 to 0.69 for cardiac death (p < 0.0001). Apixaban reduced stroke, mortality, and bleeding regardless of the NT-proBNP level.Conclusions NT-proBNP levels are often elevated in AF and independently associated with an increased risk of stroke and mortality. NT-proBNP improves risk stratification beyond the CHA2DS2VASc score and might be a novel tool for improved stroke prediction in AF. The efficacy of apixaban compared with warfarin is independent of the NT-proBNP level. (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation [ARISTOTLE]; NCT00412984).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Measurement of cardiac troponin (high-sensitivity troponin T or I) and N-terminal pro-B-type natriuretic peptide may provide additional prognostic information in selected AF patients.[380][381][382]”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [381]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Atrial fibrillation as an independent risk factor for stroke: the Framingham study
Wolf, P. A., Abbott, R. D., & Kannel, W. B. (1991) · Stroke · doi:10.1161/01.str.22.8.983 · Cited by 7,388
Lip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. G. M. (2010) · Chest · doi:10.1378/chest.09-1584 · Cited by 6,879
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493
Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Kirchhof, P. F., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Gelder, I. C. V., Al‐Attar, N., Hindricks, G., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq278 · Cited by 5,924
Impact of Atrial Fibrillation on the Risk of Death: The Framingham Heart Study
Benjamin, E. J., Wolf, P. A., D’Agostino, R. B., Silbershatz, H., Kannel, W. B., & Levy, D. (1998) · Circulation · doi:10.1161/01.cir.98.10.946 · Cited by 4,575
Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J. G. M., & Lip, G. Y. H. (2010) · CHEST Journal · doi:10.1378/chest.10-0134 · Cited by 4,517
Plasma Natriuretic Peptide Levels and the Risk of Cardiovascular Events and Death
Wang, T. J., Larson, M. G., Levy, D. A., Benjamin, E. J., Leip, E. P., Omland, T., Wolf, P. A., & Vasan, R. S. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031994 · Cited by 1,521
Yasue, H., Yoshimura, M., Sumida, H., Kikuta, K., Kugiyama, K., Jougasaki, M., Ogawa, H., Okumura, K., Mukoyama, M., & Nakao, K. (1994) · Circulation · doi:10.1161/01.cir.90.1.195 · Cited by 1,331
The Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary Syndromes
de Lemos, J. A., Morrow, D. A., Bentley, J. H., Omland, T., Sabatine, M. S., McCabe, C. H., Hall, C., Cannon, C. P., & D, E. B. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011053 · Cited by 1,280
Friberg, L., Rosenqvist, M., & Lip, G. Y. H. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr488 · Cited by 1,192
Plasma brain natriuretic peptide concentration: impact of age and gender
Redfield, M. M., Rodeheffer, R. J., Jacobsen, S. J., Mahoney, D. W., Bailey, K. R., & Burnett, J. C. J. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02059-4 · Cited by 1,140
Daniels, L. B., & Maisel, A. S. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.021 · Cited by 994
Tsutamoto, T., Wada, A., Maeda, K., 久永, 智., Maeda, Y., 深井, 大., Ohnishi, M., Sugimoto, Y., & Kinoshita, M. (1997) · Circulation · doi:10.1161/01.cir.96.2.509 · Cited by 960
N-Terminal Pro–B-Type Natriuretic Peptide and Long-Term Mortality in Stable Coronary Heart Disease
Kragelund, C., Grønning, B. A., Køber, L., Hildebrandt, P. R., & Steffensen, R. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042330 · Cited by 631
James, S. K., Lindahl, B., Siegbahn, A., Stridsberg, M., Venge, P., Armstrong, P. W., Barnathan, E. S., Califf, R. M., Topol, E. J., Simoons, M. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000079170.10579.dc · Cited by 576
Fonarow, G. C., Peacock, W. F., Phillips, C. O., Givertz, M. M., & Lopatin, M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.037 · Cited by 562
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-8-199804150-00005 · Cited by 510
Lópes, R. D., Alexander, J. H., Al‐Khatib, S. M., Ansell, J., Diaz, R., Easton, J. D., Gersh, B. J., Granger, C. B., Hanna, M., Horowitz, J. D., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2009.07.035 · Cited by 457
Hijazi, Z., Oldgren, J., Andersson, U., Connolly, S. J., Ezekowitz, M. D., Hohnloser, S. H., Reilly, P. A., Vinereanu, D., Siegbahn, A., Yusuf, S., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.038729 · Cited by 402
Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay
Yeo, K.-T. J., Wu, A. H. B., Apple, F. S., Kroll, M. H., Christenson, R. H., Lewandrowski, K. B., Sedor, F. A., & Butch, A. W. (2003) · Clinica Chimica Acta · doi:10.1016/j.cccn.2003.08.016 · Cited by 297
Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation
Inoue, S., Murakami, Y., Sano, K., Katoh, H., & Shimada, T. (2000) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(00)90010-1 · Cited by 236
Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation
Inoue, S., Murakami, Y., Sano, K., Katoh, H., & Shimada, T. (2000) · Journal of Cardiac Failure · doi:10.1054/jcaf.2000.8185 · Cited by 196
Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction
Arakawa, N., Nakamura, M., Aoki, H., & Hiramori, K. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(96)00067-8 · Cited by 194
Ellinor, P. T., Low, A. F.-H., Patton, K. K., Shea, M. A., & MacRae, C. A. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.09.045 · Cited by 175
Pisters, R., Lane, D. A., Nieuwlaat, R., Crijns, H., & Lip, G. Y. H. (2012) · Cited by 171
Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use
Boomsma, F. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00195-x · Cited by 162
Brain natriuretic peptide is elevated in outpatients with atrial fibrillation
Silvet, H., Young‐Xu, Y., Walleigh, D. J., & Ravid, S. (2003) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.07.010 · Cited by 139
Atrial secretion of B-type natriuretic peptide
Goetze, J. P. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl109 · Cited by 120
Comments on ‘Integrated discrimination and net reclassification improvements—Practical advice’
Pencina, M. J., D’Agostino, R. B., D’Agostino, R. B., & Vasan, R. S. (2007) · Statistics in Medicine · doi:10.1002/sim.3106 · Cited by 112
Wożakowska−Kapłon, B. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.03.013 · Cited by 107
Shelton, R. J. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl233 · Cited by 97
Biochemical indicators of cardiac and renal function in a healthy elderly population
Johnston, N., Jernberg, T., Lindahl, B., Lindbäck, J., Stridsberg, M., Larsson, A. O., Venge, P., & Wallentin, L. C. (2003) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2003.11.002 · Cited by 89
Patrick Jourdain, M., Bellorini, M., Funck, F., Fulla, Y., Guillard, N., Loiret, J., Thébault, B., Sadeg, N., & Desnos, M. (2002) · European Journal of Heart Failure · doi:10.1016/s1388-9842(02)00004-1 · Cited by 67
Yamada, T., Murakami, Y., Okada, T., Okamoto, M., Shimizu, T., Toyama, J., Yoshida, Y., Tsuboi, N., Ito, T., Muto, M., et al. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.071 · Cited by 54
Freynhofer, M. K., Járai, R., Höchtl, T., Bruno, V., Vogel, B., Aydınkoç-Tuzcu, K., Nürnberg, M., Wojta, J., & Huber, K. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.02.043 · Cited by 17
Cited by
Sorted by citations
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P. F., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castellà, M., Diener, H., Heidbüchel, H., Hendriks, J., et al. (2016) · EP Europace · doi:10.1093/europace/euw295 · Cited by 6,438
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezw313 · Cited by 1,403
Goetze, J. P., Bruneau, B. G., Ramos, H. R., Ogawa, T., de Bold, M. L. K., & de Bold, A. J. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0381-0 · Cited by 572
Hijazi, Z., Oldgren, J., Lindbäck, J., Alexander, J. H., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Held, C., Hylek, E. M., Lopes, R. D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00741-8 · Cited by 490
Metadata
- Authors
- Hijazi, Z., Wallentin, L., Siegbahn, A., Andersson, U., Christersson, C., Ezekowitz, J., Gersh, B. J., Hanna, M., Hohnloser, S., Horowitz, J., Huber, K., Hylek, E. M., Lopes, R. D., McMurray, J. J. V., & Granger, C. B.
- Affiliations
- Uppsala University (SE)
- University of Alberta (CA)
- Mayo Clinic (US)
- Bristol-Myers Squibb (United States) (US)
- Goethe University Frankfurt (DE)
- The University of Adelaide (AU)
- Wilhelminen Hospital (AT)
- Boston University (US)
- Western Infirmary (GB)
- Duke Medical Center (US)
- Corresponding author
- Hijazi, Ziad
- ORCID
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 61
- Issue
- 22
- Pages
- 2274-2284
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W189243586
- Cited by
- 231
- References
- 39
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 17 · 2023: 21 · 2022: 14 · 2021: 15 · 2020: 19 · 2019: 23 · 2018: 22 · 2017: 22 · 2016: 27 · 2015: 11 · 2014: 14 · 2013: 8
- FWCI
- 13.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Funders
- Bristol-Myers Squibb, Co.
- Pfizer Inc.
- Bristol-Myers Squibb Co.
- Boehringer-Ingelheim
- AstraZeneca, Merck/Schering-Plough, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline
- AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, Schering-Plough
- Boehringer-Ingelheim, AstraZeneca, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, and Schering-Plough/Merck
- AstraZeneca and Boehringer-Ingelheim
- Bristol-Myers Squibb/Pfizer
- Alere, AstraZeneca, Amgen, Abbott, Servier, Johnson & Johnson, Pfizer, and Bristol-Myers Squibb
- sanofi-aventis, St. Jude Medical, Boehringer-Ingelheim, Cardiome, Pfizer, Bayer, and Bristol-Myers Squibb
- sanofi-aventis, Bristol-Myers Squibb, Pfizer, Boehringer-Ingelheim, Medtronic, and St. Jude Medical
- Bristol-Myers Squibb and Pfizer
- AstraZeneca, Bristol-Myers Squibb/Pfizer, Boehringer-Ingelheim, Bayer, Daiichi Sankyo, and sanofi-aventis
- Johnson & Johnson, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Pfizer, and Ortho-McNeil-Janssen
- Boehringer Ingelheim and Bayer
- Bristol-Myers Squibb, AstraZeneca, Boehringer-Ingelheim, and Daiichi Sankyo
- Bristol-Myers Squibb and Boehringer-Ingelheim
- Bristol-Myers Squibb, Boehringer-Ingelheim, Astellas, AstraZeneca, GlaxoSmithKline, Medtronic Foundation, Merck, sanofi-aventis, and the Medicines Company
- Bristol-Myers Squibb, Pfizer, Boehringer-Ingelheim, AstraZeneca, Eli Lily, GlaxoSmithKline, Hoffman-La Roche, Novartis, Otsuka, Sanofi-Aventis, and the Medicines Company
- Pfizer, Novartis, Otsuka, and Hoffmann-La Roche
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- atrial fibrillation, apixaban, stroke risk stratification, CHA2DS2-VASc score, cardiovascular mortality, systemic embolism, risk prediction, ARISTOTLE trial, warfarin, bleeding risk, biomarkers, prognosis, natriuretic peptides, cardiovascular risk
- MeSH terms
- Aged, Anticoagulants, Atrial Fibrillation, Embolism, Female, Fibrinolytic Agents, Humans, Male, Peptide Fragments, Prognosis, Pyrazoles, Pyridones, Warfarin, Biomarkers, Multivariate Analysis, Proportional Hazards Models, Risk Assessment, Natriuretic Peptide, Brain, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
